Clínic-IDIBAPS optimizes its academic CAR-T therapy against multiple myeloma to address relapse
Researchers from Clínic-IDIBAPS, as part of the Clínic Barcelona Comprehensive Cancer Centre — a centre driven by Clínic, IDIBAPS and the Universit...
Researchers from Clínic-IDIBAPS, as part of the Clínic Barcelona Comprehensive Cancer Centre — a centre driven by Clínic, IDIBAPS and the Universit...
A study led by the Clínic Barcelona Comprehensive Cancer Center —a center driven by Clínic-IDIBAPS and the University of Barcelona (UB)— demonstrat...
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved AR...
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy target...
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this canc...
People who have a haematological disease, such as lymphoma or leukaemia, present a state of immunosuppression caused both by the illness itself and...
In recent years, one of the strategies developed in the field of haematology is the modification of the patient’s immune system, also known as ‘imm...
Patients with multiple myeloma and mobility problems who receive treatment at home improve their quality of life by avoiding repeated visits to the...